Study of an inhaled drug for adults with non-CF bronchiectasis
Part of Lungs & breathing clinical trials.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with non-CF bronchiectasis (confirmed by a CT scan of your chest).
- You have had at least 2 lung infections treated with antibiotics in the past year, or 1 infection plus a high symptom score on a breathing questionnaire.
- Your lung function (FEV1) is more than 35% of predicted normal and at least 1 liter after using a bronchodilator.
- You have not had a lung infection requiring antibiotics in the 4 weeks before starting the study.
- You do not have other major lung diseases like COPD or asthma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This trial tests an inhaled drug called Rev-56 in healthy adults and in adults with non-cystic fibrosis bronchiectasis who have a chronic lung infection with Pseudomonas aeruginosa. It aims to see if the drug is safe, well-tolerated, and helps reduce the bacteria in the lungs.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.